Press Releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Dec 21, 2018
Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company, announced today that it has been selected to present LPCN 1144 results as part of the 2019 NASH-TAG Conference. The presentation...
-
Dec 20, 2018
Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company, announced today that it has been selected to present LPCN 1144 clinical results as part of the Keystone Symposia on Integrated...
-
Nov 7, 2018
Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company, today announced financial results for the three and nine months ended September 30, 2018. Third Quarter and Recent Corporate...
-
Nov 5, 2018
Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company, today announced the completion of enrollment in the proof-of-concept clinical study with LPCN 1144 to assess liver fat changes in...
-
Nov 1, 2018
Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company, today announced the completion of enrollment in the ambulatory blood pressure ("ABPM") clinical study for TLANDO™, the Company's...
-
Oct 11, 2018
Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company, announced today that it has been selected to present LPCN 1144 results as part of the late-breaker session of The Liver Meeting®...
-
Sep 25, 2018
Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company, announced today that Dr. Mahesh Patel, Chairman, President and CEO, will provide a corporate overview at the Ladenburg Thalmann...
-
Aug 7, 2018
Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company, today announced financial results for the three and six months ended June 30, 2018. Second Quarter and Recent Corporate Highlights...
-
Aug 2, 2018
Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company, announced today that Dr. Mahesh Patel, Chairman, President and CEO, will provide a corporate overview at the Canaccord Genuity...
-
Jun 7, 2018
Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company, today announced the dosing of the first subject in the ambulatory blood pressure ("ABPM") clinical study for TLANDO™, the...
-
May 9, 2018
Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company, announced today that it has received a Complete Response Letter ("CRL") from the United States Food and Drug Administration...
-
May 7, 2018
Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company, today announced financial results for the first quarter ended March 31, 2018. First Quarter and Recent Corporate Highlights The...
-
Mar 21, 2018
Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company, announced today that Dr. Mahesh Patel, Chairman, President and CEO, will provide a corporate overview at the 17th Annual Needham...
-
Mar 14, 2018
Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company, announced today that Dr. Mahesh Patel, Chairman, President and CEO, will provide a corporate overview at the Oppenheimer 28th...
-
Mar 12, 2018
Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company, today announced financial results for the fourth quarter and fiscal year ended December 31, 2017. Fourth Quarter and Recent...
-
Mar 5, 2018
Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company, announced today that Dr. Mahesh Patel, Chairman, President and Chief Executive Officer, will provide a corporate overview at the...
-
Feb 16, 2018
Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company, announced today that the Company and the other defendants have entered into a memorandum of understanding to settle the purported...
-
Feb 8, 2018
Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company, announced the receipt of $10.0 million in January 2018 by means of a Loan and Security Agreement between the Company and its...
-
Feb 7, 2018
Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company, announced today that Dr. Mahesh Patel, Chairman, President and CEO, will provide a corporate overview at the LEERINK Partners 7th...
-
Jan 10, 2018
Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company, today announced that the Bone, Reproductive and Urologic Drugs Advisory Committee ("BRUDAC") of the U.S. Food and Drug...
-
Nov 17, 2017
SALT LAKE CITY, Nov. 17, 2017 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced the U.S. Food and Drug Administration ("FDA") has extended the...
-
Nov 8, 2017
SALT LAKE CITY, Nov. 08, 2017 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced financial results for the three and nine months ended September...
-
Oct 18, 2017
SALT LAKE CITY, Oct. 18, 2017 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced the U.S. Food and Drug Administration ("FDA") has scheduled the...
-
Sep 21, 2017
SALT LAKE CITY , Sept. 21, 2017 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced that the Patent Trial and Appeal Board ("PTAB") of the United...
-
Sep 20, 2017
SALT LAKE CITY, Sept. 20, 2017 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced that the Bone, Reproductive and Urologic Drugs Advisory Committee ("